Invesaro

Stocks DMII Financial statements

Financial statements

Drugs Made In America Acquisition II Corp. financial statements

Income statement, balance sheet and cash flow statement for the last 1 fiscal years, taken from the XBRL data Drugs Made In America Acquisition II Corp. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

FY2025
General and administrative0.49
Operating expenses0.49
Operating income-0.49
Interest income4.93
Other non-operating income4.68
Net income4.19

Balance sheet

FY2025
Cash and equivalents0
Other current assets0.03
Total current assets0.03
Total assets505
Accounts payable0.1
Accrued liabilities0.09
Total current liabilities0.3
Total liabilities17.8
Retained earnings-17.8
Shareholders' equity-17.8
Total equity-17.8
Total liabilities and equity505
Shares outstanding13.7

Cash flow statement

FY2025
Net income4.19
Change in payables0.1
Cash from operations-1.02
Cash from investing-500
Cash from financing501
Net change in cash-0.02

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $10.16 on September 25, 2026.

Profitability

MetricValueHow it is calculated
Return on assets (ROA)2.5%Net income / average total assets.

Balance sheet health

MetricValueHow it is calculated
Current ratio0.34xCurrent assets / current liabilities.
Quick ratio0.27x(Cash + short-term investments + receivables) / current liabilities.
Cash ratio0.27x(Cash + short-term investments) / current liabilities.
Liabilities / assets3.5%Total liabilities / total assets.
Working capital-$426.8KCurrent assets - current liabilities.
Tangible book value-$17.9MShareholders' equity - goodwill - intangible assets.

Per share

MetricValueHow it is calculated
Book value per share-$1.31Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share-$1.31Tangible book value / shares outstanding.
Cash per share$0.01(Cash + short-term investments) / shares outstanding.

Valuation

MetricValueHow it is calculated
Market cap$647.2MShare price x shares outstanding.
Enterprise value$647.0MMarket cap + total debt - cash - short-term investments.
P/E49.7xMarket cap / net income. Only when net income is positive.
Earnings yield2.0%Net income / market cap (the inverse of P/E).
Was Drugs Made In America Acquisition II Corp. profitable in fiscal 2025?

Yes. Net income was $4.2M, a net margin of -.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Drugs Made In America Acquisition II Corp.